0
Skip to Content
Low Grade Glioma Registry
LGG Registry
LGG Registry Eligibility
OPTIMUM
Firefighters and Glioma
LGG Quality of Life
Clinical Trials
Gallery
LGG Information
Astrocytoma
Oligodendroglioma
Webinars
Disability Benefits
Spanish LGG Webinar
Returning to work
Sleep Webinar
IDH+ Glioma Treatments Webinar
FAQ
Registro de GBG
Criterios del Registro de GBG
Estudio OPTIMUM
Preguntas Frecuentes
Galería
Webinarios
Lo que usted necesita saber acerca de GBG
Concientización de los tumores cerebrales en la comunidad Hispana/Latina
Información acerca de GBG
Astrocitomas
Oligodendrogliomas
Brain Tumor Awareness
Salud America
Hispanic Heritage Month
BTAM 2025
BTAM 2024
Español/Spanish
English/Inglés
Join the Registry
Low Grade Glioma Registry
LGG Registry
LGG Registry Eligibility
OPTIMUM
Firefighters and Glioma
LGG Quality of Life
Clinical Trials
Gallery
LGG Information
Astrocytoma
Oligodendroglioma
Webinars
Disability Benefits
Spanish LGG Webinar
Returning to work
Sleep Webinar
IDH+ Glioma Treatments Webinar
FAQ
Registro de GBG
Criterios del Registro de GBG
Estudio OPTIMUM
Preguntas Frecuentes
Galería
Webinarios
Lo que usted necesita saber acerca de GBG
Concientización de los tumores cerebrales en la comunidad Hispana/Latina
Información acerca de GBG
Astrocitomas
Oligodendrogliomas
Brain Tumor Awareness
Salud America
Hispanic Heritage Month
BTAM 2025
BTAM 2024
Español/Spanish
English/Inglés
Join the Registry
LGG Registry
LGG Registry Eligibility
OPTIMUM
Firefighters and Glioma
LGG Quality of Life
Clinical Trials
Gallery
Folder: LGG Information
Back
Astrocytoma
Oligodendroglioma
Folder: Webinars
Back
Disability Benefits
Spanish LGG Webinar
Returning to work
Sleep Webinar
IDH+ Glioma Treatments Webinar
FAQ
Registro de GBG
Criterios del Registro de GBG
Estudio OPTIMUM
Preguntas Frecuentes
Galería
Folder: Webinarios
Back
Lo que usted necesita saber acerca de GBG
Concientización de los tumores cerebrales en la comunidad Hispana/Latina
Folder: Información acerca de GBG
Back
Astrocitomas
Oligodendrogliomas
Folder: Brain Tumor Awareness
Back
Salud America
Hispanic Heritage Month
BTAM 2025
BTAM 2024
Español/Spanish
English/Inglés
Join the Registry
Research Advisory Council (RAC) Members of our Low-Grade Glioma Registry OPTIMUM project gather as part of the Quality of Life Roundtable Meeting in Washington, DC with the National Brain Tumor Society - May 2023.

Research Advisory Council (RAC) Members of our Low-Grade Glioma Registry OPTIMUM project gather as part of the Quality of Life Roundtable Meeting in Washington, DC with the National Brain Tumor Society - May 2023.

LGG Registry and OPTIMUM research associate, Annie Heffernan, MPH, was presented with a Junior Investigator Award, sponsored by the American Brain Tumor Association (2023 Brain Tumor Epidemiology Consortium Annual Meeting).
You may read more of her w

LGG Registry and OPTIMUM research associate, Annie Heffernan, MPH, was presented with a Junior Investigator Award, sponsored by the American Brain Tumor Association (2023 Brain Tumor Epidemiology Consortium Annual Meeting). You may read more of her work at: https://pe-cgs.org/resources/

The Genomic Characterization Unit (GCU) at OPTIMUM is led by co-Principal Investigator Roel Verhaak, PhD. The GCU is responsible for studying genetic changes among recurrent glioma tumors.

The Genomic Characterization Unit (GCU) at OPTIMUM is led by co-Principal Investigator Roel Verhaak, PhD. The GCU is responsible for studying genetic changes among recurrent glioma tumors.

Annie Heffernan (right), LGG Registry/OPTIMUM research associate, represents the Brigham and Women's Department of Neurosurgery at the 2023 NBTS New England Brain Tumor Walk.

Annie Heffernan (right), LGG Registry/OPTIMUM research associate, represents the Brigham and Women's Department of Neurosurgery at the 2023 NBTS New England Brain Tumor Walk.

Annie Heffernan (Research Associate, right), Elizabeth Claus (LGG Registry founder, center), and Mathew Krick (Research Associate, left) representing OPTIMUM's Participant Engagement Unit (PEU) at the Participant Engagement in Cancer Genomic Sequenci

Annie Heffernan (Research Associate, right), Elizabeth Claus (LGG Registry founder, center), and Mathew Krick (Research Associate, left) representing OPTIMUM's Participant Engagement Unit (PEU) at the Participant Engagement in Cancer Genomic Sequencing annual meeting in Albuquerque, New Mexico.

OPTIMUM team members gather at the 2023 Participant Engagement and Cancer Genomic Sequencing (PE-CGS) Annual Meeting in Albuquerque, New Mexico. PE-CGS is a broader network for which OPTIMUM is a part of.

OPTIMUM team members gather at the 2023 Participant Engagement and Cancer Genomic Sequencing (PE-CGS) Annual Meeting in Albuquerque, New Mexico. PE-CGS is a broader network for which OPTIMUM is a part of.

Researchers across the Participant Engagement and Cancer Genomic Sequencing network meet at the 2023 annual American Association for Cancer Research (AACR) conference in San Diego, California

Researchers across the Participant Engagement and Cancer Genomic Sequencing network meet at the 2023 annual American Association for Cancer Research (AACR) conference in San Diego, California

San Diego, California - 
Dr. Elizabeth Claus discusses engaging Latino communities in the LGG Registry at the 2024 AACR Annual Meeting in a presentation titled "Optimizing Engagement of Latino Communities to Promote Equity in Low Grade Glioma Genomic

San Diego, California - Dr. Elizabeth Claus discusses engaging Latino communities in the LGG Registry at the 2024 AACR Annual Meeting in a presentation titled "Optimizing Engagement of Latino Communities to Promote Equity in Low Grade Glioma Genomic Research (OPEL)" Dr. Claus and collaborators of the LGG registry aim to advance representation and equity in glioma research. To view Dr. Claus' slides, please click on the image to be redirected.

Cancer Moonshot Seminar Series - 
On May 23, Ms. Liz Salmi from OPTIMUM and Dr. Kai Tan from Children's Hospital of Philadelphia jointly presented on the topic "Advancing Data Sharing through the Cancer Moonshot" during the Cancer Moonshot Seminar Se

Cancer Moonshot Seminar Series - On May 23, Ms. Liz Salmi from OPTIMUM and Dr. Kai Tan from Children's Hospital of Philadelphia jointly presented on the topic "Advancing Data Sharing through the Cancer Moonshot" during the Cancer Moonshot Seminar Series organized by the National Cancer Institute. Learn more from the recorded seminar.

OPTIMUM researchers, participants, and community partners attend the 2024 Participant Engagement and Cancer Genome Sequencing Annual Meeting in St. Louis, Missouri to share study updates and discuss best practices for engaging research participants a

OPTIMUM researchers, participants, and community partners attend the 2024 Participant Engagement and Cancer Genome Sequencing Annual Meeting in St. Louis, Missouri to share study updates and discuss best practices for engaging research participants and communicating research results.

© 2024 Low Grade Glioma Registry

Download/Descargar:

Low Grade Glioma Registry consent form - English (PDF)

Formulario de consentimiento para el registro - Spanish (PDF)

OPTIMUM consent form - English [PDF]

Formulario de consentimiento para OPTIMUM - Spanish [PDF]

Yale IRB Protocol ID: 1604017628
NIH Project Number: 1U2CCA252979-01A1

Study Eligibility
FAQ
Research Team
Privacy Policy

Yale School of Public Health
Biostatistics – Low Grade Glioma Registry

P.O. Box 208034
60 College Street
New Haven, CT 06520-0834
Office: 203.785.6415
Fax: 203.785.6912
Email: glioma@yale.edu